Neuroendocrinology

Original Paper

Noradrenergic Innervation of the Hypothalamus Participates in Adrenocortical Responses to Interleukin-1

Chuluyan H.E. · Saphier D. · Rohn W.M. · Dunn A.J.

Author affiliations

Department of Pharmacology and Therapeutics, Louisiana State University Medical Center, Shreveport, La., USA

Related Articles for ""

Neuroendocrinology 1992;56:106–111

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: September 19, 1991
Accepted: November 25, 1991
Published online: April 07, 2008
Issue release date: 1992

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: https://www.karger.com/NEN

Abstract

Stress and immune activation are associated with increases in plasma concentrations of corticosterone (CS). To determine whether the catecholaminergic innervation of neurons in the hypothalamic paraventricular nucleus (PVN) is involved in these responses, selective lesions were made using 6-hydroxydopamine (6-OHDA). Injection of 6-OHDA into the PVN depleted its norepin-phrine (NE) content by 85% and reduced by 80-82% the increase in plasma CS concentrations following intraperitoneal injection of recombinant human interleukin-1α (IL-1), but did not affect the adrenocortical response to 20 min restraint. Injection of 6-OHDA into the ventral noradrenergic ascending bundle depleted PVN NE content by 77%. This lesion reduced the CS response to human IL-1α by 82-86%, but did not alter that to 20 min restraint, although there was a nonsignificant decrease in the CS response following 3 min of restraint. These results suggest that the noradrenergic innervation of the PVN mediates the activation of the hypothalamic-pituitary-adrenal (HPA) axis by intraperitoneally injected IL-1. There may be a noradrenergic contribution to the HPA response to restraint, but other neural pathways probably also participate in this response.

© 1992 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: September 19, 1991
Accepted: November 25, 1991
Published online: April 07, 2008
Issue release date: 1992

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0

ISSN: 0028-3835 (Print)
eISSN: 1423-0194 (Online)

For additional information: https://www.karger.com/NEN


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP